Get trade alerts

BeOne Medicines ($ONC) Insider Trading & Smart Money Activity

BeOne Medicines AG · Biotechnology · Latest filing Oct 13, 2026

BeOne Medicines AG ($ONC) has 11 insider trades and 4 analyst ratings on file. In the last 12 months on the open market, no insider bought and 5 insiders sold ($24.21M), net -$24.21M.

Insider buyers (12 mo)
0
Insider sellers (12 mo)
5
Net insider $ (12 mo)
-$24.21M
Congress trades (12 mo)
0
13F moves on file
0
Analyst ratings on file
4

ONC insider buying and selling by quarter

QuarterInsider buysInsider salesCongress buys / sales13F added / cut
Q1 2026 0 0 0 / 0 0 / 0
Q2 2026 0 3 · $1.59M 0 / 0 0 / 0
Q3 2026 0 2 · $11.74M 0 / 0 0 / 0
Q4 2026 0 1 · $10.89M 0 / 0 0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All ONC insider, congress, 13F and analyst activity

DateSourceWhoActionSharesValue / amount ΔOwn1W1M6MFilingStory
Insider Wang XiaodongDirector Sell (Open-market sale) 10b5-1 31.03K sh $10.89M Read
Analyst RBC Capital Reiterates to Outperform PT $459 +6.8% —
Analyst Truist Securities Reiterates to Buy PT $420 -3.4% —
Analyst JP Morgan Reiterates to Overweight PT $445 -2.4% —
Insider Lee Chan HenrySVP, General Counsel Sell (Open-market sale) 10b5-1 1.11K sh $418.12K -0.5% —
Insider Wang XiaodongDirector Sell (Open-market sale) 10b5-1 31.03K sh $11.32M -1.5% —
Analyst Citizens Reiterates to buy PT $396 +3.8%+8.7% Read
Insider Xiaobin WuPresident and COO Sell (Open-market sale) 1.29K sh $356.93K +3.2%+18.3% —
Insider Lai WangPresident, Global Head of R&D Sell (Open-market sale) 1.07K sh $295.56K +3.2%+18.3% Read
Insider John OylerChief Executive Officer Sell (Open-market sale) 3.41K sh $933.59K +3.2%+18.3% —
Insider Xiaodong Wang Buy (Grant or award) 193.49K sh +3.8%+16.8% Read
Insider Shalini Sharp Buy (Grant or award) 18.98K sh +3.8%+16.8% Read
Insider Sawyers Charles Lazelle Buy (Grant or award) 18.98K sh +3.8%+16.8% Read
Insider Lee Chan HenrySVP, General Counsel Buy (Grant or award) 45.07K sh +3.8%+16.8% Read
Insider Baker Bros. Advisors LP Buy (Grant or award) 37.96K sh +3.8%+16.8% —

1W / 1M / 6M = how ONC moved from the trade or filing date.

Insider trading in ONC: who is buying and selling

InsiderRoleTradesOpen-market netShares heldLast trade
Wang Xiaodong Director 2 -$22.21M Oct 13, 2026
Lee Chan Henry SVP, General Counsel 2 -$418.12K Sep 30, 2026
Xiaobin Wu President and COO 1 -$356.93K Jun 23, 2026
Lai Wang President, Global Head of R&D 1 -$295.56K Jun 23, 2026
John Oyler Chief Executive Officer 1 -$933.59K Jun 23, 2026
Xiaodong Wang 1 — Jun 11, 2026
Shalini Sharp 1 — Jun 11, 2026
Sawyers Charles Lazelle 1 — Jun 11, 2026
Baker Bros. Advisors LP 1 — Jun 11, 2026

Analyst ratings on ONC

DateFirmActionRatingPrice target1W1M6MStory
RBC Capital Reiterates Outperform $450 → $459 +6.8% —
Truist Securities Reiterates Buy $418 → $420 -3.4% —
JP Morgan Reiterates Overweight $425 → $445 -2.4% —
Citizens Reiterates buy $396 +3.8%+8.7% Read

Frequently asked questions

Are ONC insiders buying or selling?

Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 5 insiders made 6 open-market sales worth $24.21M, a net -$24.21M.

What is the latest insider trade in ONC?

Wang Xiaodong, Director filed a sell (open-market sale) of 31.03K sh worth $10.89M on Oct 13, 2026.

Other biotechnology stocks

All stocks Insider cluster buys Top insider purchases Congress 13F institutions

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.

Get trade alerts by text